⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17039367 | 0.88 | — | — | |
| SCHEMBL19803932 | 0.85 | — | — | |
| SCHEMBL17057616 | 0.83 | — | — | |
| SCHEMBL17034255 | 0.77 | TSHR (0.32) | — | |
| SCHEMBL17036736 | 0.77 | — | — | |
| SCHEMBL17036728 | 0.76 | FAP (0.34) | — | |
| SCHEMBL18307660 | 0.76 | TSHR (0.31) | — | |
| SCHEMBL18307751 | 0.76 | TSHR (0.31) | — | |
| SCHEMBL17034502 | 0.71 | TSHR (0.30) | — | |
| SCHEMBL17032642 | 0.70 | LMNA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022766-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9732104-B2 | Ether compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |